BCYC

Bicycle Therapeutics plc NASDAQ

Healthcare ·Biotechnology ·GB · bicycletherapeutics.com

$4.80

Mkt Cap $332.5M

52w Low $4.24 10.5% of range 52w High $9.55

50d MA $5.04 200d MA $6.67

P/E (TTM) -1.5x

EV/EBITDA 0.4x

P/B 0.6x

Debt/Equity 0.0x

ROE -35.9%

P/FCF -1.9x

RSI (14) —

ATR (14) —

Beta 1.65

50d MA $5.04

200d MA $6.67

Avg Volume 473.9K

About

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 30, 2026	BMO	-0.62	-0.87	-40.1%	4.73	-1.5%	-0.2%	+1.5%	—	—	—	—	—
Mar 17, 2026	BMO	-0.94	-0.29	+69.1%	5.05	+1.2%	+0.4%	-6.9%	-9.9%	-13.9%	-14.1%	+1.8%	—
Oct 30, 2025	BMO	-1.09	-0.85	+22.0%	8.18	+0.0%	+7.1%	-1.3%	-11.2%	-16.0%	-24.6%	-13.9%	—
Aug 8, 2025	BMO	-0.95	-1.14	-20.0%	7.46	+1.2%	+2.5%	+0.0%	-3.2%	-1.5%	-1.1%	-6.2%	—
May 1, 2025	BMO	-0.86	-0.88	-2.3%	8.56	+1.6%	+6.1%	+8.6%	+5.8%	-13.6%	-9.1%	-0.1%	—
Feb 25, 2025	BMO	-0.85	-0.80	+5.9%	11.25	+0.0%	-1.3%	+0.6%	-2.0%	-2.5%	-6.9%	-18.3%	—
Oct 31, 2024	BMO	-0.78	-0.74	+5.1%	24.03	-3.0%	-2.4%	-5.5%	-2.4%	-2.2%	-1.6%	-16.7%	—
Aug 6, 2024	BMO	-1.10	-0.77	+30.0%	22.71	-1.4%	+7.4%	-0.7%	+1.1%	+2.1%	+1.5%	-10.0%	—
May 2, 2024	BMO	-1.26	-0.62	+50.8%	24.20	+3.0%	+2.0%	+1.6%	-3.7%	-4.6%	-2.4%	-4.8%	—
Feb 20, 2024	BMO	-1.23	-1.16	+5.7%	22.50	-1.8%	+0.8%	+3.1%	+6.6%	+9.5%	+13.6%	+14.9%	—
Nov 2, 2023	BMO	-1.06	-1.26	-18.9%	15.35	+3.4%	-2.9%	+1.2%	-4.3%	-0.7%	-0.1%	-2.6%	—
Aug 3, 2023	BMO	-1.10	-1.41	-28.2%	23.16	-1.2%	-0.1%	+1.3%	+0.9%	-2.8%	-2.9%	-5.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 8	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.90	$5.07	+3.5%	+1.6%	+1.4%	+0.8%	+1.6%	+3.3%
Mar 18	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$5.07	$5.12	+1.0%	-7.3%	-10.3%	-14.2%	-14.4%	-11.2%
Mar 18	Oppenheimer	Maintains	Outperform → Outperform	—	$5.07	$5.12	+1.0%	-7.3%	-10.3%	-14.2%	-14.4%	-11.2%
Mar 18	Citizens	Maintains	Market Outperform → Market Outperform	—	$5.07	$5.12	+1.0%	-7.3%	-10.3%	-14.2%	-14.4%	-11.2%
Mar 18	Needham	Maintains	Buy → Buy	—	$5.07	$5.12	+1.0%	-7.3%	-10.3%	-14.2%	-14.4%	-11.2%
Oct 31	RBC Capital	Downgrade	Outperform → Sector Perform	—	$8.76	$8.23	-6.1%	-7.9%	-17.1%	-21.6%	-29.6%	-25.7%
Oct 31	Citizens	Maintains	Market Outperform → Market Outperform	—	$8.76	$8.23	-6.1%	-7.9%	-17.1%	-21.6%	-29.6%	-25.7%
Aug 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$7.46	$7.42	-0.5%	-3.2%	-1.5%	-1.1%	-0.3%	+1.1%
Aug 12	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$7.46	$7.42	-0.5%	-3.2%	-1.5%	-1.1%	-0.3%	+1.1%
Aug 11	Oppenheimer	Maintains	Outperform → Outperform	—	$7.65	$7.75	+1.3%	-2.5%	-5.6%	-3.9%	-3.5%	-2.7%
Jul 17	RBC Capital	Maintains	Outperform → Outperform	—	$7.78	$7.66	-1.5%	+3.3%	+10.0%	+6.8%	+7.6%	+12.0%
May 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$9.06	$9.03	-0.3%	-18.3%	-14.1%	-9.7%	-7.9%	-5.1%
May 2	B. Riley Securities	Maintains	Neutral → Neutral	—	$9.08	$9.44	+4.0%	+2.4%	-0.2%	-18.5%	-14.3%	-9.9%
May 2	RBC Capital	Maintains	Outperform → Outperform	—	$9.08	$9.44	+4.0%	+2.4%	-0.2%	-18.5%	-14.3%	-9.9%
May 2	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$9.08	$9.44	+4.0%	+2.4%	-0.2%	-18.5%	-14.3%	-9.9%
May 2	Needham	Maintains	Buy → Buy	—	$9.08	$9.44	+4.0%	+2.4%	-0.2%	-18.5%	-14.3%	-9.9%
May 1	Barclays	Maintains	Overweight → Overweight	—	$8.56	$8.70	+1.6%	+6.1%	+8.6%	+5.8%	-13.6%	-9.1%
Apr 29	Needham	Maintains	Buy → Buy	—	$8.40	$8.40	+0.0%	-2.3%	+1.9%	+8.1%	+10.7%	+7.9%
Apr 9	Needham	Maintains	Buy → Buy	—	$6.38	$6.27	-1.7%	+7.8%	+2.4%	+5.0%	+10.8%	+22.1%
Mar 11	Needham	Maintains	Buy → Buy	—	$9.79	$9.78	-0.1%	+4.2%	+6.2%	-1.6%	-1.0%	+1.9%
Feb 26	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$11.10	$11.09	-0.1%	+2.0%	-0.6%	-1.2%	-5.7%	-8.6%
Feb 26	Needham	Maintains	Buy → Buy	—	$11.10	$11.09	-0.1%	+2.0%	-0.6%	-1.2%	-5.7%	-8.6%
Feb 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.10	$11.09	-0.1%	+2.0%	-0.6%	-1.2%	-5.7%	-8.6%
Jan 22	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$13.56	$13.37	-1.4%	-2.7%	-2.4%	-4.3%	-3.8%	-3.0%
Jan 13	Needham	Maintains	Buy → Buy	—	$13.31	$13.74	+3.2%	+13.9%	+11.3%	+9.3%	+2.1%	+0.2%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.31	$13.74	+3.2%	+13.9%	+11.3%	+9.3%	+2.1%	+0.2%
Dec 18	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$15.14	$16.47	+8.8%	+1.2%	-0.9%	-3.0%	-4.0%	-3.0%
Dec 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.81	$13.88	+0.5%	+9.5%	+9.6%	+10.9%	+8.6%	+6.3%
Dec 13	B. Riley Securities	Maintains	Neutral → Neutral	—	$20.11	$17.29	-14.0%	-31.3%	-24.8%	-24.7%	-23.8%	-25.4%
Nov 1	RBC Capital	Maintains	Outperform → Outperform	—	$23.45	$23.31	-0.6%	-3.2%	+0.0%	+0.3%	+0.8%	+5.3%
Nov 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.45	$23.31	-0.6%	-3.2%	+0.0%	+0.3%	+0.8%	+5.3%
Oct 31	Needham	Maintains	Buy → Buy	—	$24.03	$23.30	-3.0%	-2.4%	-5.5%	-2.4%	-2.2%	-1.6%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.32	$25.20	-0.5%	-2.2%	-2.3%	-2.1%	-3.4%	-5.1%
Oct 24	Needham	Maintains	Buy → Buy	—	$25.32	$25.20	-0.5%	-2.2%	-2.3%	-2.1%	-3.4%	-5.1%
Sep 16	Needham	Maintains	Buy → Buy	—	$27.02	$27.38	+1.3%	-7.6%	-9.7%	-9.8%	-5.6%	-6.0%
Sep 16	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$27.02	$27.38	+1.3%	-7.6%	-9.7%	-9.8%	-5.6%	-6.0%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.02	$27.38	+1.3%	-7.6%	-9.7%	-9.8%	-5.6%	-6.0%
Sep 9	Needham	Maintains	Buy → Buy	—	$20.54	$21.00	+2.2%	+28.3%	+31.6%	+31.3%	+32.6%	+31.5%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.38	$23.48	-3.7%	-7.5%	-5.8%	-4.9%	-5.5%	-8.2%
Aug 7	Needham	Maintains	Buy → Buy	—	$24.38	$23.48	-3.7%	-7.5%	-5.8%	-4.9%	-5.5%	-8.2%
Aug 7	Oppenheimer	Maintains	Outperform → Outperform	—	$24.38	$23.48	-3.7%	-7.5%	-5.8%	-4.9%	-5.5%	-8.2%
Aug 7	B. Riley Securities	Downgrade	Buy → Neutral	—	$24.38	$23.48	-3.7%	-7.5%	-5.8%	-4.9%	-5.5%	-8.2%
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.69	$25.33	+2.6%	-0.4%	-5.6%	-6.5%	-4.3%	-4.5%
Apr 10	Needham	Maintains	Buy → Buy	—	$23.07	$22.77	-1.3%	-0.3%	-2.5%	-3.3%	-5.4%	-4.9%
Feb 21	Needham	Maintains	Buy → Buy	—	$22.69	$23.34	+2.9%	+2.2%	+5.7%	+8.6%	+12.6%	+15.0%
Feb 21	Canaccord Genuity	Maintains	Buy → Buy	—	$22.69	$23.34	+2.9%	+2.2%	+5.7%	+8.6%	+12.6%	+15.0%
Feb 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.69	$23.34	+2.9%	+2.2%	+5.7%	+8.6%	+12.6%	+15.0%
Dec 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$17.81	$18.00	+1.1%	+1.5%	+3.1%	+4.8%	+4.5%	+3.9%
Dec 15	Needham	Maintains	Buy → Buy	—	$15.00	$14.98	-0.1%	+16.7%	+18.0%	+18.7%	+20.5%	+22.5%
Nov 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$15.25	$15.28	+0.2%	+0.6%	-7.9%	-12.9%	-10.1%	-3.7%

Recent Filings

8-K

Bicycle Therapeutics plc -- 8-K Filing

Bicycle Therapeutics' lead EphA2 candidate nuzefatide pevedotin shows promise across 150+ patients in oncology trials, potentially positioning the company competitively against existing cancer therapies.

Apr 30

8-K · 8.01 !! High

Bicycle Therapeutics plc -- 8-K 8.01: Material Event / Announcement

I need the actual content of the press release or announcement to provide a specific analysis of what this means for investors. The summary provided only references that a press release exists but doesn't describe the material event itself. Could you provide the actual announcement details?

Apr 20

8-K · 5.02 !!! Very High

Bicycle Therapeutics plc -- 8-K 5.02: Executive Change

Bicycle Therapeutics appointed Travis Thompson as CFO while he resigned from the board, indicating leadership restructuring that separates financial oversight from board governance roles.

Feb 3

Data updated apr 26, 2026 9:50am · Source: massive.com